FIGHTING CHRONIC DISEASE

We are developing best-in-class ultra-long-acting medicines for chronic viral infections and CNS disorders, where better adherence and compliance can dramatically improve patient outcomes.

OUR APPROACH

PRODRUG NANOMEDICINE

Exavir prodrug nano-formulation technology can prolong the apparent half-life of small molecule drugs by >100X.

Our first mission: eliminate the spread of HIV

1200000

Estimated infections in the US

40000000

Estimated infections worldwide

>$ 30000000000

Annual drug sales in HIV category

900 %

Increase in healthcare costs for HIV+ vs HIV-

1 in 4

Patients are fully adherent to treatment

9 out of 10

Prefer long-acting therapy to daily oral therapy

99 %

Risk-reduction when HIV PrEP is taken as prescribed

BEST-IN-CLASS AGENTS

Exavir’s small molecule platform technology enables ultra-long-acting dosing regiments that provide convenience, safety, and efficacy advantages compared to existing options.

EXAVIR NANOCRYSTALS

Exavir programs have the potential to impact nearly 100 million patients across HIV, opioid use disorder, and schizophrenia.

HIV INTEGRASE

MU OPIOID RECEPTOR

MUSCARINIC M4 RECEPTOR

ULTRA-LONG-ACTING INJECTABLES

Exavir prodrugs enable optimal properties and enable novel composition of matter.

Exavir formulation technology allows for extended release and ultra-long-acting dosing interval.